Objective We aimed to determine the epidermal growth factor receptor （EGFR） mutation status and treatment survival of patients with stage IV lung adenocarcinoma living in the Ordos area of Inner Mongolia, China. Met...Objective We aimed to determine the epidermal growth factor receptor （EGFR） mutation status and treatment survival of patients with stage IV lung adenocarcinoma living in the Ordos area of Inner Mongolia, China. Methods EGFR testing and first-line tyrosine kinase inhibitor （TKI） treatment rates of patients with stage IV lung adenocarcinoma were analyzed from June 2012 to June 2016. Kaplan-Meier survival curves were constructed to compare patients who received different treatment strategies and those harboring different EGFR mutation statuses. Results EGFR testing and mutation rates were 65.60% and 52.90%, respectively, and improved continuously from June 2012 to June 2016. Among patients with EGFR mutations, 38.9% had EGFR 19 del, 48.2% had L858R, 4.2% had co-existing mutations in exons 19 and 21, and 8.4% had uncommon mutations. The median overall survival （OS） was 29.5, 26.5, and 16.0 months for patients receiving both TKI and chemotherapy, TKI alone, and chemotherapy alone, respectively （P = 0.047）. The OS was 26.5 and 30.0 months for patients harboring EGFR 19 del and L858R mutations, respectively （P = 0.096）. Conclusion The high OS rates of stage IV lung adenocarcinoma patients living in the Ordos area may be attributed to continuous improvements in EGFR testing and first-line TKI treatment rates. In the era of TKIs, chemotherapy for increasing OS times should be emphasized.展开更多
基金Supported by a grant from the Inner Mongolia Health Planning Committee Sciences Foundation(No.201303164)Wu Jie Ping Funding(No.320675014017)
文摘Objective We aimed to determine the epidermal growth factor receptor （EGFR） mutation status and treatment survival of patients with stage IV lung adenocarcinoma living in the Ordos area of Inner Mongolia, China. Methods EGFR testing and first-line tyrosine kinase inhibitor （TKI） treatment rates of patients with stage IV lung adenocarcinoma were analyzed from June 2012 to June 2016. Kaplan-Meier survival curves were constructed to compare patients who received different treatment strategies and those harboring different EGFR mutation statuses. Results EGFR testing and mutation rates were 65.60% and 52.90%, respectively, and improved continuously from June 2012 to June 2016. Among patients with EGFR mutations, 38.9% had EGFR 19 del, 48.2% had L858R, 4.2% had co-existing mutations in exons 19 and 21, and 8.4% had uncommon mutations. The median overall survival （OS） was 29.5, 26.5, and 16.0 months for patients receiving both TKI and chemotherapy, TKI alone, and chemotherapy alone, respectively （P = 0.047）. The OS was 26.5 and 30.0 months for patients harboring EGFR 19 del and L858R mutations, respectively （P = 0.096）. Conclusion The high OS rates of stage IV lung adenocarcinoma patients living in the Ordos area may be attributed to continuous improvements in EGFR testing and first-line TKI treatment rates. In the era of TKIs, chemotherapy for increasing OS times should be emphasized.
